BIO Submits Comments on Proprietary Naming

The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA, the Agency) for the opportunity to submit comments on the Draft Guidance for Industry on Best Practices in Developing Proprietary Names for Drugs.
BIO commends FDA on releasing this Draft Guidance, which will help guide Sponsors as they choose proprietary names that will minimize the potential for medication errors or misbranding.